Diabetes
NEW TYPE 2 DIABETES WEIGHT LOSS STUDY
Intro: This Phase 3 clinical trial will study an experimental weight loss drug, eloralintide, which has helped some study participants lose up to 11.5% of their body weight at 12 weeks in an early-stage trial.
Investigational Drug: The drug is a long- acting form of the normal gluco-regulatory hormone amylin which has benefits similar to the GLP-1s in studies so far. The study drug might result in fewer side effects and provide an additional treatment option for patients.
To Qualify: Persons diagnosed with T2D for at least 6 months, with an A1C under 10%, on stable treatment with either diet/exercise alone or up to 3 orral meds for diabetes, aged 18 or over, not currently on insulin or other weight loss meds.
Goal: To assess the effect of the investigational medication on weight loss and A1C in persons with Type 2 Diabetes and overweight condition.